These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 19155198)

  • 21. The androgen receptor in hormone-refractory prostate cancer.
    Mao HL; Zhu ZQ; Chen CD
    Asian J Androl; 2009 Jan; 11(1):69-73. PubMed ID: 19050686
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel, potent anti-androgens of therapeutic potential: recent advances and promising developments.
    Vasaitis TS; Njar VC
    Future Med Chem; 2010 Apr; 2(4):667-80. PubMed ID: 21426013
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Androgen receptor as a target in androgen-independent prostate cancer.
    Balk SP
    Urology; 2002 Sep; 60(3 Suppl 1):132-8; discussion 138-9. PubMed ID: 12231070
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Androgen receptor: role and novel therapeutic prospects in prostate cancer.
    Taplin ME
    Expert Rev Anticancer Ther; 2008 Sep; 8(9):1495-508. PubMed ID: 18759700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hormone treatment for prostate cancer: current issues and future directions.
    Ichikawa T; Suzuki H; Ueda T; Komiya A; Imamoto T; Kojima S
    Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():58-63. PubMed ID: 16273367
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of the androgen receptor in the development and progression of prostate cancer.
    Jenster G
    Semin Oncol; 1999 Aug; 26(4):407-21. PubMed ID: 10482183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications.
    Aurilio G; Cimadamore A; Mazzucchelli R; Lopez-Beltran A; Verri E; Scarpelli M; Massari F; Cheng L; Santoni M; Montironi R
    Cells; 2020 Dec; 9(12):. PubMed ID: 33321757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lessons from in-vivo models of castration-resistant prostate cancer.
    Lin D; Gout PW; Wang Y
    Curr Opin Urol; 2013 May; 23(3):214-9. PubMed ID: 23385975
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate Cancer.
    Silberstein JL; Taylor MN; Antonarakis ES
    Curr Urol Rep; 2016 Apr; 17(4):29. PubMed ID: 26902623
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells.
    Godoy-Tundidor S; Hobisch A; Pfeil K; Bartsch G; Culig Z
    Clin Cancer Res; 2002 Jul; 8(7):2356-61. PubMed ID: 12114440
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours.
    Culig Z; Steiner H; Bartsch G; Hobisch A
    Endocr Relat Cancer; 2005 Jun; 12(2):229-44. PubMed ID: 15947099
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Androgen receptor signaling in androgen-refractory prostate cancer.
    Grossmann ME; Huang H; Tindall DJ
    J Natl Cancer Inst; 2001 Nov; 93(22):1687-97. PubMed ID: 11717329
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiandrogens in prostate cancer endocrine therapy.
    Culig Z; Bartsch G; Hobisch A
    Curr Cancer Drug Targets; 2004 Aug; 4(5):455-61. PubMed ID: 15320720
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Molecular mechanisms involved in hormone resistance of prostate cancer].
    Cabrespine A; Guy L; Chollet P; Debiton E; Bay JO
    Bull Cancer; 2004 Oct; 91(10):747-57. PubMed ID: 15556875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer.
    Chatterjee B
    Mol Cell Biochem; 2003 Nov; 253(1-2):89-101. PubMed ID: 14619959
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alterations of androgen receptor in prostate cancer.
    Linja MJ; Visakorpi T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):255-64. PubMed ID: 15663988
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The androgen receptor can signal through Wnt/beta-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens.
    Schweizer L; Rizzo CA; Spires TE; Platero JS; Wu Q; Lin TA; Gottardis MM; Attar RM
    BMC Cell Biol; 2008 Jan; 9():4. PubMed ID: 18218096
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Marked response to cabazitaxel in prostate cancer xenografts expressing androgen receptor variant 7 and reversion of acquired resistance by anti-androgens.
    Ylitalo EB; Thysell E; Thellenberg-Karlsson C; Lundholm M; Widmark A; Bergh A; Josefsson A; Brattsand M; Wikström P
    Prostate; 2020 Feb; 80(2):214-224. PubMed ID: 31799745
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Minireview: Alternative activation pathways for the androgen receptor in prostate cancer.
    Lamont KR; Tindall DJ
    Mol Endocrinol; 2011 Jun; 25(6):897-907. PubMed ID: 21436259
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel inducible transactivation domain in the androgen receptor: implications for PRK in prostate cancer.
    Metzger E; Müller JM; Ferrari S; Buettner R; Schüle R
    EMBO J; 2003 Jan; 22(2):270-80. PubMed ID: 12514133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.